Probiotic Bacteria for Neurodevelopmental Disorder Behavior
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autism spectrum disorder (ASD) and schizophrenia lack effective solutions for improving communication behavior and sensorimotor gating performance, which are often impaired in individuals with these conditions.
Innovation Solution
Administration of specific probiotic compositions comprising Enterococcus bacteria, such as E. faecalis, and Bacteroides bacteria, like B. fragilis and B. thetaiotaomicron, which are administered separately or in combination to improve sensorimotor gating and communication behaviors, with the bacteria being free from other contaminants to ensure efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for ASD and schizophrenia, then current standard therapies are applied, but they fail to effectively improve communication behavior and sensorimotor gating performance
Solution Approach 1:
The patent changes the fundamental parameter of treatment approach by transitioning from conventional pharmaceutical or behavioral therapies to probiotic-based intestinal microbiota modulation. This parameter change targets the gut-brain axis, fundamentally altering how treatment efficacy is achieved by modifying intestinal bacteria composition rather than directly treating neurological symptoms
Solution Approach 2:
The patent introduces intestinal microbiota as an intermediary mechanism between treatment and neurological outcomes. Rather than directly affecting brain function, the probiotic compositions act through the gut-brain axis, using intestinal bacteria as a mediator to indirectly improve communication behavior and sensorimotor gating performance
2Productivity
If probiotic compositions are administered to improve behavioral symptoms, then communication behavior and sensorimotor gating performance improve, but the treatment requires specific bacterial strains free from contaminants to ensure efficacy
Solution Approach 1:
The patent applies local quality by specifying particular bacterial strains (Enterococcus faecalis and Bacteroides species) with distinct functional properties. Each strain is selected for its specific probiotic characteristics, creating a composition where different bacterial components fulfill specialized roles in improving neurological symptoms through the gut-brain axis
3Reliability
If multiple bacterial strains are combined in probiotic compositions, then treatment efficacy is enhanced, but the complexity of composition formulation and quality control increases
Solution Approach 1:
The patent merges multiple probiotic bacterial strains (Enterococcus faecalis and various Bacteroides species) into a single compositional framework. This combining approach leverages the synergistic effects of different bacterial strains, where each contributes unique probiotic functions that collectively enhance treatment efficacy for neurological symptoms
Solution Approach 2:
The patent creates a composite probiotic composition comprising multiple bacterial strains with complementary functions. This composite approach integrates different microbial components that work together through the gut-brain axis, combining the benefits of strain diversity while maintaining a structured formulation framework
Data Source
AI summary
Some embodiments include bacterial species for use in treatment of one or more autism spectrum disorder (ASD), and/or schizophrenia symptoms in a subject in need thereof. The bacterial species can include Bacteroides (e.g., B. fragilis, B. thetaiotaomicron, and/or B. vulgatus), and/or Enterococcus (e.g., E. faecalis, E. faecium, E. hirae, E. avium, E. durans, E. gallinarum, or E. casseliflavus). Upon treatment, one or more ASD-related behaviors can be improved in the subject.